New Data Position Lazertinib As Strong Contender In 1L NSCLC

South Korea's Yuhan Corporation has unveiled promising top-line Phase III data for its novel cancer drug lazertinib in the first-line treatment of epidermal growth factor receptor (EGFR) mutation-positive, advanced non-small cell lung cancer (NSCLC), concluding the drug will be competitive as a monotherapy and raising hopes for a second standard-of-care option for a form of the malignancy seen more frequently in Asia.

The top-line findings from the LASER301 study, presented at the ESMO (European Society for Medical Oncology) Asia Congress held in Singapore on 2-4 December, showed the oral EGFR tyrosine kinase...